Biotech Values

[corpstrat]

Zetia - Do people here think the analysts are merely spinning with some of these comments? One thing to say that the stock prices already reflected the Enhance result, another thing to imply the Enhance result will have no effect on Vytorin / Zetia revenues, as the GS guy appears to do, no?


http://www.cnbc.com/id/22649697/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo

From Huckman

Miller Tabak healthcare analyst Les Funtleyder writes in a research note to clients this morning why that [ minor stock drop] appears to be the case. "MRK has more than enough pipeline to in-line products to overcome some marketing challenges to Vytorin," he says.

Bernstein's Tim Anderson writes, "Results look benign relative to expectations." And he points out that Vytorin showed a "minor" liver-safety edge. While Goldman Sachs' Jim Kelly says, "ENHANCE trial nonevent. (And) we believe that this result does not represent a relevant difference for assessing the commercial prospects for Vytorin."

Bernstein owns at least one percent of MRK and SGP. GS has done and wants to do more investment banking for both companies and makes a market in both of their stocks.